CT38

CT38 is an experimental peptide (i.e., two or more amino acids linked in a chain) that acts as an agonist for CRF2 (corticotropin-releasing factor 2). CT38 is available as the drug Cortene.

Clinicians
Lucinda Bateman is the principal investigator for a current clinical trial of CT38 for ME/CFS, it is only being tested on patients who meet both the Canadian Consensus Criteria for myalgic encephalomyelitis and the Fukuda criteria for chronic fatigue syndrome.

Articles, talks and interviews

 * 2018, The Cortene Chronic Fatigue Syndrome (ME/CFS) Drug Trial Begins

Learn more

 * Clinical Trial to Investigate CT38 in the Treatment og Myalgic Encephalomyelitis / Chronic Fatigue Syndrome
 * Science - Hypothesis behind CT38